Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Response to systemic therapy in fumarate hydratase-deficient renal cell carcinomaLucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, et al.
Journal of Oncology|February 28, 2022
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter StudyCharles Vauchier, Edouard Auclin, Philippe Barthélémy, et al.
The Journal of Urology|September 16, 2020
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial CarcinomaXiao X Wei, Lillian Werner, Min Y Teo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinomaLucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, et al.
Journal for Immunotherapy of Cancer|May 31, 2022
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 studyLucia Carril-Ajuria, Aude Desnoyer, Maxime Meylan, et al.
The Oncologist|August 18, 2022
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell CarcinomasJonathan Thouvenin, Omar Alhalabi, Maria Carlo, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
European Urology Oncology|January 11, 2021
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint InhibitorsAli Raza Khaki, Ang Li, Leonidas N Diamantopoulos, et al.
BJU International|February 8, 2021
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomesStepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
BJU International|October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancerDimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Pageof 3